Lantian Wang
Overview
Explore the profile of Lantian Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Z, Wang L, Wu P, Yuan L
Appl Microbiol Biotechnol
. 2025 Jan;
109(1):2.
PMID: 39754636
Bacteria-based tumor therapy, which releases therapeutic payloads or remodels the tumor's immune-suppressive microenvironment and directly kills tumor cells or initiates an anti-tumor immune response, is recently recognized as a promising...
2.
Lai Y, Tao W, Wang L, Liu Z, Wu P, Yang G, et al.
Biotechnol J
. 2024 Dec;
19(12):e202400561.
PMID: 39726053
Ultrasound (US) can easily penetrate media with excellent spatial precision corresponding to its wavelength. Naturally, US plays a pivotal role in the echolocation abilities of certain mammals such as bats...
3.
Wang L, Liu Z, Ji P, Ma J, Mou K, Zhou T, et al.
Small
. 2024 Nov;
:e2405549.
PMID: 39511869
Immunotherapy involving PDL1 degradation holds great potential in anti-tumor treatment. Optimal design of PDL1 degraders and subsequent efficient delivery into tumors are essential for expected efficacy, especially when abnormal tumor...
4.
Liu J, Li H, Wang L, Wang S, Tang Q
J Transl Med
. 2024 Jul;
22(1):702.
PMID: 39075485
Background: The intricacies of nucleotide metabolism within tumor cells specific to colorectal cancer (CRC) remain insufficiently characterized. A nuanced examination of particular tumor clusters and their dynamic interplay with the...
5.
Liang Y, Zhang S, Wang D, Ji P, Zhang B, Wu P, et al.
Adv Healthc Mater
. 2024 Jul;
13(31):e2401274.
PMID: 39031111
Accurately evaluating tumor neoangiogenesis and conducting precise interventions toward an immune-favorable microenvironment are of significant clinical importance. In this study, a novel nanodroplet termed as the nanodroplet-based ultrasound contrast agent...
6.
Ji P, Wu P, Wang L, Wang Y, Guo X, Gao R, et al.
Small
. 2024 Jun;
20(43):e2400770.
PMID: 38934533
Increased expression of immune check point genes, such as PD-L1, is one of the main reasons for immunosuppression, especially for colon cancer. Development of novel therapeutic strategies is of great...
7.
Wang L, Li X, Wu J, Tang Q
Diabetes Metab Syndr Obes
. 2023 Oct;
16:3133-3145.
PMID: 37842335
Background: Cancers trigger systemic metabolic disorders usually associated with glucose intolerance, which is an initially apparent phenomenon. One of the features of pancreatic cancer (PC) metabolic reprogramming is the crosstalk...
8.
LncRNA SNHG20 silencing inhibits hepatocellular carcinoma progression by sponging miR-5095 from MBD1
Xu B, Li C, Yang B, Zhou F, Tang K, Wang L, et al.
Am J Transl Res
. 2023 Jul;
15(6):4314-4331.
PMID: 37434830
Objective: Long non-coding RNAs (lncRNAs) may have a significant regulatory effect on the progression of hepatocellular carcinoma (HCC), according to recent data. This study aims to investigate how SNHG20, a...
9.
Cheng C, Chen J, Su H, Chen J, Rao Q, Yang J, et al.
Glob Chang Biol
. 2023 Jul;
29(17):5000-5013.
PMID: 37428468
Positive feedback is key to producing alternative stable states and largely determines ecological resilience in response to external perturbations. Understanding the positive feedback mechanisms in macrophyte-dominated lakes is crucial for...
10.
Tang K, Chen Q, Liu Y, Wang L, Lu W
J Cancer
. 2022 Sep;
13(11):3234-3243.
PMID: 36118519
Hepatocellular carcinoma (HCC) is one of the most lethal cancers in the world. Sorafenib is the first small-molecule multi-kinase inhibitors approved by FDA for treatment of advanced HCC. Metformin has...